Clinical Manifestation and Incidence of Cardiopulmonary Complications in Early Systemic Sclerosis (SSc) Patients with Different Antibody Profiles. It was found that the presence of SSc-specific autoantibodies was associated with a distinctive clinical presentation and cumulative internal organ involvement, even in the early phase of the disease. PubMed, J Clin Med Res, 2019 Jul;11(7):524-531. (Also see Antibodies and Research about Scleroderma Cardiac (Heart) Involvement)
Pneumoproteins KL-6 and CCL-18 Predict Progression of Interstitial Lung Disease in Systemic Sclerosis (SSc-ILD). In a rigorously-conducted clinical trial for SSc-ILD, KL-6 and CCL-18 levels correlated with ILD severity and declined with immunosuppression. PubMed, Arthritis Rheumatol, 06/24/2019. (Also see Pulmonary Fibrosis)
Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis (dSSc): a European Scleroderma Trials and Research (EUSTAR) analysis. The use of the predictive factors presented here could enable cohort enrichment with patients at risk for overall disease worsening in SSc clinical trials. PubMed, Ann Rheum Dis, 06/21/2019. (Also see Diffuse Scleroderma)
Anti-cancer Therapy May Help Fight Inflammation in Scleroderma (SSc) Patients, Data Suggest. These results suggest that tagraxofusp might be a potential therapeutic approach for SSc or other autoimmune diseases. Scleroderma News, 06/26/2019. (Also see Cancer and Dendritic Cells)
Colonic and Anorectal Manifestations of Systemic Sclerosis. Colonic and anorectal manifestations of systemic sclerosis include constipation, diarrhea, and fecal incontinence, and can diminish quality of life for these patients. PubMed, Curr Gastroenterol Rep, 2019 Jul 8;21(7):33. (Also see Bowel Dysfunction)
GI Manifestations With a Focus on the Esophagus: Recent Progress in Understanding Pathogenesis. The improvement of diagnostic tools for esophageal symptoms and dysfunction offer an opportunity to improve the characterization of scleroderma esophageal disease. PubMed, Curr Rheumatol Rep, 2019 Jul 3;21(8):42. (Also see Esophageal Involvement)
Cancers in systemic sclerosis (Ssc) : risk factors, impact on survival and literature review The history of renal scleroderma crisis and the positivity of anti-topoisomerase I antibodies were associated with an increased risk of cancer in SSc patients in this monocentric study. PubMed, Rev Med Interne, 06/26/2019. (Also see Cancer)
Antibodies against specific extractable nuclear antigens (ENAs) as diagnostic and prognostic tools and inducers of a profibrotic phenotype in cultured human skin fibroblasts: are they functional? This study suggests a pathogenic role of scleroderma-specific autoantibodies to directly induce pro-fibrotic activation in human dermal fibroblasts. PubMed, Arthritis Res Ther, 2019 Jun 24;21(1):152. (Also see Fibroblasts and Antibodies)
B cell depletion treatment decreases CD4+IL4+ and CD4+CD40L+ T cells in patients with systemic sclerosis (SSc). Our study demonstrates a link between rituximab treatment and CD4+IL4+ T cell decrease both in the skin and peripheral blood of patients with SSc. PubMed, Rheumatol Int, 06/21/2019. (Also see Biologic Agents and B Cells and T Cells)
Stem cell enriched lipotransfer reverses the effects of fibrosis in systemic sclerosis. Autologous stem cell enriched lipotransfer significantly improved the effects of oro-facial fibrosis in SSc in this open cohort study. PubMed, PLoS One, 2019 Jul 17;14(7):e0218068. (Also see Stem Cell (Bone Marrow) Transplantation)
TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.
We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: